Biogen Q4 EPS Beats by 23.6% as Revenue Tops Estimates by 3.1%
Biogen reported Q4 EPS of $1.99, surpassing the $1.61 consensus by 23.6%, while revenue of $2.28 billion exceeded estimates by 3.1% despite a year-over-year decline from $2.40 billion. Shares rose about 1.2% in premarket trading as investors reacted to the earnings beat.
1. Premarket Performance
In premarket trading Biogen shares climbed approximately 1.2% following the release of Q4 earnings, contributing to broader gains in the tech and biotech sectors that saw major indices trading higher by up to 0.76%.
2. Quarterly Earnings Detail
Biogen delivered Q4 EPS of $1.99, beating the $1.61 estimate by 23.6%, while revenue reached $2.28 billion versus a $2.21 billion consensus, marking a 3.1% upside despite a 5% year-over-year revenue decline from $2.40 billion.
3. Product Performance
Sales of Biogen’s Alzheimer’s treatment continued to drive growth, offsetting declines in other franchises; the company highlighted stable demand for its neurology portfolio as the primary revenue contributor.
4. Market Implications
The stronger-than-expected results may support a re-rating of Biogen’s valuation multiple, with analysts evaluating potential upward revisions to 2026 guidance and comparing Biogen’s performance to other large-cap biotech peers.